HIV / AIDS in the News

HIV care providers are running out of medicine thanks to Trump’s foreign aid cuts - Yahoo

 

Starting the HIV PrEP Conversation in Primary Care and Pharmacy - Patient Care Online

 

H.I.V. Research Networks Face Uncertain Future Amid Funding Delays - The New York Times

 

SF to recognize PrEP day for first time - Bay Area Reporter

 

IU scientist awarded nearly $3 million by NIH to investigate a key barrier to HIV cure - Department of Biology: Indiana University Bloomington

 

HIV care providers are running out of medicine thanks to Trump’s foreign aid cuts - Advocate.com

 

​Former Miss USA: Renew Trump's goal to end HIV by 2030 - Advocate.com

 

Plateau develops five-year plan as HIV donor funding declines - Premium Times Nigeria

 

Beyond Viral Suppression: Holistic HIV Care and Remaining Treatment Gaps - Pharmacy Times

 

Lenacapavir for HIV Treatment vs Prevention: Avoiding Pharmacy Dispensing Errors - Pharmacy Times

 

Thai monk handed 50-year prison sentence for misusing donations to HIV and Aids hospice - The Independent

 

HIV Testing Before and During PrEP: Getting It Right - Drug Topics

 

Anktiva May Help Shrink HIV Viral Reservoir - POZ

 

HIV Testing Before and During PrEP: Getting It Right - Patient Care Online

 

Starting the HIV PrEP Conversation in Primary Care and Pharmacy - Drug Topics

 

ViiV's Cabenuva enhances control of unsuppressed HIV - pharmaphorum

 

Lenacapavir PrEP Is Safe and Effective During Pregnancy - POZ

 

Clinical Guidance for PEP | HIV Nexus - Centers for Disease Control and Prevention | CDC (.gov)

 

The Latest Resources from AVAC: The Power of Coalition Advocacy - AVAC

 

HIV and Health Financing Technical Experts and NAC Directors’ Meeting Opens in Dar es Salaam to Accelerate HIV Prevention and Sustainability | SADC - SADC

 

ST Pharm's HIV drug STP0404 shows no serious adverse events in US phase 2a trial - Korea Biomedical Review

 

Older Age Linked to Better Quality of Life in Adults With HIV After ART Switch - Infectious Disease Advisor

 

LEN won’t sell itself: 6 lessons from HIV prevention pills - Bhekisisa

 

CATIE | Canadian study links cardiovascular disease to declining brain health - European AIDS Treatment Group

 

HIV i-Base | Unexpected viral rebound with GLP-1 weight loss drugs in HIV study - European AIDS Treatment Group

 

HIV Testing Ban Backlash: Bar employee pens emotional letter - WDSU

 

University of British Columbia | HPV vaccine offers lasting protection for women living with HIV, study finds - European AIDS Treatment Group

 

[Press release] ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with viremia - European AIDS Treatment Group

 

After the ICU Door Closes: One in Four HIV Patients Rehospitized or Dead - Bioengineer.org

 

LSE | New study finds major HIV service declines in Uganda and Zimbabwe after 2025 US aid cuts - European AIDS Treatment Group